%D9%86%D8%A7%D9%84%D8%AA%D8%B1%D9%8A%D9%83%D8%B3%D9%88%D9%86%D9%86%D8%A7%D9%84%D8%AA%D8%B1%D9%88%DA%A9%D8%B3%D8%A7%D9%86%D0%9D%D0%B0%D0%BB%D1%82%D1%80%D0%B5%D0%BA%D1%81%D0%BE%D0%BDCategory:NaltrexoneNaltrexonNaltrecsonNaltrexonNaltrexoneNaltrexona%D9%86%D8%A7%D9%84%D8%AA%D8%B1%D9%88%DA%A9%D8%B3%D8%A7%D9%86NaltreksoniNaltrexone%D7%A0%D7%9C%D7%98%D7%A8%D7%A7%D7%A1%D7%95%D7%9FNaltrex%C3%B3nNaltrexone%EB%82%A0%ED%8A%B8%EB%A0%89%EC%86%90NaltrexonNaltrekson%E0%AC%A8%E0%AC%BE%E0%AC%B2%E0%AC%9F%E0%AD%8D%E0%AC%B0%E0%AD%87%E0%AC%95%E0%AD%8D%E0%AC%B8%E0%AD%8B%E0%AC%A8NaltreksonNaltrexona%D0%9D%D0%B0%D0%BB%D1%82%D1%80%D0%B5%D0%BA%D1%81%D0%BE%D0%BDNaltreksonNaltrexoneNaltreksonNaltrexon%D0%9D%D0%B0%D0%BB%D1%82%D1%80%D0%B5%D0%BA%D1%81%D0%BE%D0%BDNaltrexoneQ409587
about
Evaluation of Intranasal Naltrexone and NaloxoneStudy of Subcutaneous Methylnaltrexone (MNTX) in the Treatment of Opioid-Induced Constipation During Rehabilitation After Orthopedic ProceduresA Safety and Efficacy Study of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects Participating in an Intensive Behavior Modification ProgramInjectable Versus Oral Naltrexone Treatment of Alcohol Dependence In Serious Mental Illness (SMI)Injectable Naltrexone Treatment of Alcohol Dependence in Serious Mental Illness (SMI)A Study of Embeda (Kadian NT, ALO-01) in Subjects With Pain Due to Osteoarthritis of the Hip or KneeStudy of Bupropion Versus Bupropion + Naltrexone for Smoking CessationMedication and Counseling for Controlled Drinking (Project SMART)Targeted Naltrexone for Problem DrinkersEffectiveness of Naltrexone Versus Placebo to Reduce Craving for Alcohol With Evaluation of Genetic Variability.Efficacy and Safety Study of Combination Therapy to Treat Uncomplicated ObesityAdherence to HIV Therapy in Heroin Addicts: Oral vs XR-NTXExtended Release Naltrexone for Treating Amphetamine Dependence in IcelandSafety Study to Assess Opiate Withdrawal Signs and Symptoms in Opioid Dependent PatientsAlcohol Pharmacotherapy for HIV+ PrisonersDepot Naltrexone Mechanism of Action in Heroin Dependent Patients Using fMRI and SPECTEffect of Naltrexone on Counterregulatory Mechanisms in HypoglycemiaHealthy Volunteers Study to Estimate the Effects of Food on the Bioavailability of Oxycodone and Naltrexone/6- Β -Naltrexol From a Extended Release Formulation of Oxycodone With Sequestered NaltrexoneA Study of VIVITROL in the Prevention of Re-arrest and Re-incarcerationExtended-Release Naltrexone to Treat Methamphetamine Dependence in Men Who Have Sex With Men (MSM)Extended-Release Naltrexone Opioid Treatment at Jail Re-EntryThe Effect of Buprenorphine Delivered by Buprenorphine Transdermal System (BTDS) at Doses up to 80 Micrograms/Hour (mcg/hr) and Naltrexone on Electrocardiogram (ECG) Intervals in Healthy VolunteersControl of Cognition (Naltrexone, Methylphenidate, and ADHD Study (NMAS))Targeting GABA and Opioid Systems for a Pharmacotherapy for Methamphetamine AbuseALK21-018: Effects of Medisorb® Naltrexone (VIVITROL®) on Alcohol Craving in Treatment-seeking, Alcohol-dependent AdultsNaltrexone and Varenicline: Weight Gain and Tolerability in Cigarette SmokersA Randomized Placebo-Controlled, Crossover-Design Study of the Effects of Low Dose NaltrexoneALK21-014: Efficacy and Safety of Medisorb® Naltrexone (VIVITROL®) After Enforced AbstinenceLong Acting Naltrexone for Opioid Addiction: Focus on Sustained Abstinence and RecoveryStudy for Naltrexone on the Abuse Potential of MethylphenidateMedication Maintenance Therapy in Community Pharmacy SettingsMOM NEST Study: Maternal Opioid Medication: Naltrexone Efficacy StudyDrug Treatment for Depressed Alcoholics (Naltrexone/Fluoxetine)Study of a Novel Subcutaneous Depot Formulation of BuprenorphineNaltrexone, Craving, and DrinkingEffect of Topical Naltrexone Ophthalmic Solution on the Signs and Symptoms of Dry Eye in Diabetic SubjectsNaltrexone Plus Ketamine for the Rapid Treatment of Major Depressive Disorder and Alcohol Use DisorderManaging Alcoholism in People Who Do Not Respond to NaltrexoneTargeted Interventions for Weight-Concerned SmokersLow Dose Naltrexone to Improve Physical Health in Patients With Vasculitis
P4844
An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1ANaltrexone for cocaine dependence treatmentLow dose naltrexone for induction of remission in Crohn's diseaseLow dose naltrexone for induction of remission in Crohn's diseaseNaltrexone for cocaine dependence treatmentOral naltrexone maintenance treatment for opioid dependenceOral naltrexone maintenance treatment for opioid dependenceSustained-Release Naltrexone For Opioid DependenceOral naltrexone maintenance treatment for opioid dependenceSustained-Release Naltrexone For Opioid DependenceNaltrexone maintenance treatment for opioid dependenceTreatment of Complex Regional Pain Syndrome (CRPS) using low dose naltrexone (LDN)Fibromyalgia symptoms are reduced by low-dose naltrexone: a pilot studyIntermittent marijuana use is associated with improved retention in naltrexone treatment for opiate-dependenceAn evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) studyPharmacokinetics, safety, and tolerability of a depot formulation of naltrexone in alcoholics: an open-label trial.The Need for Psychosocial Interventions to Facilitate the Transition to Extended-Release Naltrexone (XR-NTX) Treatment for Opioid Dependence: A Concise Review of the LiteratureNaltrexone HCI/bupropion HCI for chronic weight management in obese adults: patient selection and perspectivesRisks and Benefits of Nalmefene in the Treatment of Adult Alcohol Dependence: A Systematic Literature Review and Meta-Analysis of Published and Unpublished Double-Blind Randomized Controlled TrialsThe efficacy and safety of the naltrexone/bupropion combination for the treatment of obesity: an updateThe μ-opioid receptor and treatment response to naltrexoneNaltrexone sustained-release/bupropion sustained-release for the management of obesity: review of the data to dateImproving clinical outcomes for naltrexone as a management of problem alcohol useNaltrexone but Not Ketanserin Antagonizes the Subjective, Cardiovascular, and Neuroendocrine Effects of Salvinorin-A in HumansThe Effects of Naltrexone on Subjective Response to Methamphetamine in a Clinical Sample: a Double-Blind, Placebo-Controlled Laboratory Study.Should naltrexone be the first-line medicine to treat alcohol dependence in Aboriginal and Torres Strait Islander populations? An Australian perspectiveSafety of high-dose naltrexone treatment: hepatic transaminase profiles among outpatientsA pharmacokinetic and pharmacodynamic drug interaction study of acamprosate and naltrexoneOxytrex: an oxycodone and ultra-low-dose naltrexone formulationLow-dose naltrexone therapy improves active Crohn's diseaseAcute effects of naltrexone and GBR 12909 on ethanol drinking-in-the-dark in C57BL/6J miceNon-stereoselective reversal of neuropathic pain by naloxone and naltrexone: involvement of toll-like receptor 4 (TLR4)A pilot trial of low-dose naltrexone in primary progressive multiple sclerosisThe use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic painLetter: Treatment of accidental naltrexone-induced withdrawalA controlled trial of propoxyphene and naltrexone in patients with Tourette's syndromeThe structure-action relationship and kinetics of some naloxone and naltrexone derivativesAlpha-methyldopa induces a naltrexone-insensitive antinociception and hypomotility in ratsShort-term effects of naltrexone in 155 heroin ex-addictsHigh dose naltrexone for dyskinesias induced by levodopa
P921
description
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de
chemische Verbindung
@de-ch
chemische verbinding
@nl
name
Naltrekson
@sh
Naltrekson
@sr
Naltreksoni
@fi
Naltrexon
@cs
Naltrexon
@de
Naltrexon
@nb
Naltrexon
@nl
Naltrexon
@sv
Naltrexona
@ca
Naltrexona
@es
type
label
Naltrekson
@sh
Naltrekson
@sr
Naltreksoni
@fi
Naltrexon
@cs
Naltrexon
@de
Naltrexon
@nb
Naltrexon
@nl
Naltrexon
@sv
Naltrexona
@ca
Naltrexona
@es
altLabel
(-)naltrexone
@cy
(-)naltrexone
@en
16590-41-3
@fr
17-(Cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinan-6-one
@cy
17-(Cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinan-6-one
@en
17-(Cyclopropylmethyl)-4,5alpha-epoxy-3,14-dihydroxymorphinan-6-one
@cy
17-(Cyclopropylmethyl)-4,5alpha-epoxy-3,14-dihydroxymorphinan-6-one
@en
17-(Cyclopropylmethyl)-4,5α-epoxy-3,14-dihydroxymorphinan-6-one
@en
Antaxone
@it
C20H23N1O4
@it
prefLabel
Naltrekson
@sh
Naltrekson
@sr
Naltreksoni
@fi
Naltrexon
@cs
Naltrexon
@de
Naltrexon
@nb
Naltrexon
@nl
Naltrexon
@sv
Naltrexona
@ca
Naltrexona
@es